Thrivent Financial for Lutherans Cuts Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Thrivent Financial for Lutherans decreased its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,261 shares of the medical equipment provider’s stock after selling 1,927 shares during the period. Thrivent Financial for Lutherans’ holdings in BioLife Solutions were worth $708,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Louisiana State Employees Retirement System raised its holdings in shares of BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock worth $392,000 after purchasing an additional 700 shares during the period. GAMMA Investing LLC raised its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of BioLife Solutions by 5.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 753 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 1,374 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions during the 2nd quarter worth $35,000. Institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

BLFS has been the topic of several recent research reports. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Northland Securities upped their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Craig Hallum lifted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.50.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $26.81 on Wednesday. The firm’s 50 day simple moving average is $24.27 and its 200 day simple moving average is $23.28. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1-year low of $12.45 and a 1-year high of $28.88.

Insider Transactions at BioLife Solutions

In related news, EVP Aby J. Mathew sold 17,604 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the transaction, the executive vice president now directly owns 284,442 shares in the company, valued at approximately $5,703,062.10. This represents a 5.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,313 shares of company stock valued at $1,572,899. 2.20% of the stock is currently owned by company insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.